In a recent development, the Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert concerning the popular painkiller Meftal, raising concerns about potential adverse effects on health. Meftal, widely prescribed for conditions such as rheumatoid arthritis and menstrual cramps, contains mefenamic acid and is utilized in the treatment of various ailments, including fever, inflammation, and different types of pain.
The alert, released on November 30, is based on a preliminary analysis of adverse drug reactions sourced from the Pharmacovigilance Programme of India (PVPI) database. Of particular concern is the emergence of the Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome associated with the use of Meftal.
Patients and healthcare providers are now advised to closely monitor any potential adverse reactions linked to Meftal. The IPC emphasizes the importance of vigilance, especially for individuals using the painkiller for conditions such as dysmenorrhea, osteoarthritis, and rheumatoid arthritis. The alert underscores the need for users to be proactive in recognizing and reporting adverse drug reactions.
In the event of experiencing any such reactions, individuals are urged to promptly report the issue to the IPC’s national PVPI coordination center. This can be done through the submission of a form via the ADR PVPI Android mobile app, the PVPI Helpline No. 1800-180-3024, or the official website www.ipc.gov.in.
The IPC, an independent body under the Ministry of Health, plays a crucial role in setting guidelines for the production, marketing, and usage of all medications in India. This recent alert is part of the ongoing efforts to ensure the safety and well-being of the public in the face of emerging health concerns related to pharmaceuticals.
